Triple meeting 2024 – Revolution shows selective KRAS promise
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
ESMO 2024 – Astellas defends its degrader
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
ESMO 2024 preview – Astellas’s KRAS degrader disappoints
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
Revolution sees a new pan-KRAS challenger
Pfizer moves to take PF-07934040 into its first clinical trial.
BridgeBio’s oncology spinout must stand out from the crowd
The new developer will focus on the crowded KRAS space and PI3Kα/AKT inhibition, which has been hit by toxicity issues.
Revolution pushes home its pan-KRAS advantage
Not long after starting phase 1, RMC-6236 could be in pivotal trials this year.
